Surprising Success in Immunotherapy Treatment for Leukemia

Article

Researchers at the University of Pennsylvania have reported on the results of a trial in which a patient with chronic lymphocytic leukemia (CLL) experienced a complete remission after immunotherapy with tumor-reactive modified T cells.

Researchers at the University of Pennsylvania have reported on the results of a trial in which patients with chronic lymphocytic leukemia (CLL) experienced a complete remission after immunotherapy with tumor-reactive modified T cells. The studies were reported last week in the New England Journal of Medicine, DOI: 10.1056/NEJMoa1103849 and in the journal Science Translational Medicine.

Packaging and infection by a lentiviral vector

David Porter and his colleagues designed a lentiviral vector that expressed a chimeric antigen receptor with specificity for the B-cell antigen CD19, coupled with CD137 (a costimulatory receptor in T cells) and CD3-zeta (a signal-transduction component of the T-cell antigen receptor) signaling domains.

The researchers pretreated patients with chemotherapy with pentostatin and cyclophosphamide in order to deplete their lymphocytes. A low dose of the autologous chimeric antigen receptor–modified T cells was then reinfused into the patient.

Twenty-two days after treatment, tumor lysis syndrome was diagnosed; at this time, high levels of cytokines (interferon-γ and interleukin-6) were detected and circulating chimeric antigen receptor-positive T cells (CAR T cells) were found to have expanded to a level that was more than 1000 times as high as the initial engraftment level. Some of these CAR T cells persisted with a memory phenotype, which enabled them to respond quickly and effectively to a second exposure to CLL cells.

Indeed, eight months later, the high chimeric antigen receptor-positive T cell levels persisted, and two of the three CLL patients who underwent treatment had complete remission of their leukemia. On average, the researchers believe, each engineered T cell had killed roughly 1,000 cancer cells. The side effects from treatment included loss of normal B cells and tumor lysis syndrome.

Dr. David Porter, director of the blood and marrow transplantation program at the Hospital of the University of Pennsylvania in Philadelphia and a coauthor of both papers said that the researchers knew the therapy could be "very potent, but I don't think we expected it to be this dramatic on this go-around."

Thus far, therapy with tumor-infiltrating lymphocytes and other immunotherapies that have been clinically tested have proven to be costly and time-consuming. In an editorial in the NEJM, by Walter Urba at Oregon Health & Science University and colleagues, Urba states that “Chimeric antigen receptors have theoretical advantages over other T-cell based therapies,” but it seems that the jury is still out over whether this data will prove to have wide clinical significance.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
Related Content